NASDAQ:AUPH • CA05156V1022
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AURINIA PHARMACEUTICALS INC (AUPH).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-03 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-11-07 | Jefferies | Upgrade | Hold -> Buy |
| 2025-11-05 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-23 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-02-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-23 | RBC Capital | Reiterate | Outperform |
| 2023-01-04 | RBC Capital | Maintains | Outperform |
| 2022-11-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-04 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-11-04 | RBC Capital | Maintains | Outperform |
| 2022-11-04 | SVB Leerink | Maintains | Outperform |
| 2022-08-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-08 | Oppenheimer | Maintains | Outperform |
| 2022-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-28 | RBC Capital | Maintains | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 175.513M 30.98% | 235.133M 33.97% | 283.055M 20.38% | 332.71M 17.54% | 385.09M 15.74% | 447.99M 16.33% | 475.6M 6.16% | 527.46M 10.90% | 621.57M 17.84% | 720.17M 15.86% | 831.62M 15.48% | |
| EBITDA YoY % growth | -80.044M 26.42% | 37.864M 147.30% | 126.01M 232.80% | 162.89M 29.27% | 195.84M 20.23% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -91.691M 17.77% | 18.419M 120.09% | 106.561M 478.54% | 123.13M 15.55% | 159.73M 29.72% | 153.2M -4.09% | 216.04M 41.02% | 272.55M 26.16% | 349.58M 28.26% | 429.56M 22.88% | 518.03M 20.60% | |
| Operating Margin | -52.24% | 7.83% | 37.65% | 37.01% | 41.48% | 34.20% | 45.42% | 51.67% | 56.24% | 59.65% | 62.29% | |
| EPS YoY % growth | -0.54 28.95% | 0.09 116.67% | 0.81 800.00% | 0.82 1.75% | 1.00 20.98% | 1.30 30.26% | 0.93 -28.14% | 1.26 34.97% | 1.70 35.22% | 2.06 20.96% | 2.38 15.59% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.20 26.22% | 0.21 32.60% | 0.22 -4.21% | 0.22 -13.69% |
| Revenue Q2Q % growth | 78.938M 26.37% | 81.812M 16.86% | 83.165M 13.20% | 86.513M 12.19% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 29.922M 27.98% | 31.16M 54.28% | 30.936M 4.00% | 31.461M -5.35% |
All data in USD
13 analysts have analysed AUPH and the average price target is 17.34 USD. This implies a price increase of 8.65% is expected in the next year compared to the current price of 15.96.
AURINIA PHARMACEUTICALS INC (AUPH) will report earnings on 2026-04-30.
The consensus EPS estimate for the next earnings of AURINIA PHARMACEUTICALS INC (AUPH) is 0.2 USD and the consensus revenue estimate is 78.94M USD.
The number of analysts covering AURINIA PHARMACEUTICALS INC (AUPH) is 13.